Anti-DLL3 antibody drug conjugates for treating cancer

Patent metadata

Field	Value
Publication number	US-9775916-B1
Application number	US-201715608996-A
Country	US
Kind code	B1
Filing date	May 30, 2017
Priority date	Feb 24, 2012
Publication date	Oct 3, 2017
Grant date	Oct 3, 2017

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
L comprises a linker;
D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
n is an integer from 1 to 20.

2. The method of claim 1 , wherein the cancer is lung cancer.

3. The method of claim 2 , wherein the lung cancer is small cell lung cancer.

4. The method of claim 1 , wherein the cancer comprises a neuroendocrine tumor.

5. The method of claim 1 , wherein the cancer is large cell neuroendocrine carcinoma.

6. The method of claim 1 , wherein the cancer is thyroid cancer.

7. The method of claim 1 , wherein the cancer is prostate cancer.

8. The method of claim 1 , wherein the subject has relapsed from chemotherapy.

9. The method of claim 1 , wherein the linker comprises a cleavable linker.

10. The method of claim 1 , wherein:
R 2 is R, wherein R is a C 5-20 aryl group;
R 6 and R 9 are H;
R 7 is OR, and wherein R is a C 1 alkyl;
Q is O, and wherein R 11 is H; and/or
X and X″ are O.

11. A method of treating a tumor comprising neuroendocrine features in a subject, wherein the tumor is characterized by elevated expression of ASCL1, the method comprising administering to the subject a therapeutically effective amount of an antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
L comprises a linker;
D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O SO 2 R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and
n is an integer from 1 to 20.

12. The method of claim 11 , wherein the tumor shows suppressed Notch signaling.

13. The method of claim 11 , wherein the tumor shows elevated levels of DLL3 and/or HES6 as compared to normal tissue or non-tumorigenic cells.

14. The method of claim 11 , wherein the tumor is characterized by a poorly differentiated neuroendocrine phenotype.

15. The method of claim 11 , wherein the tumor occurs in lung, genitourinary tract, gastrointestinal tract, thyroid, or kidney.

16. The method of claim 15 , wherein the tumor comprises small cell lung cancer.

17. The method of claim 15 , wherein the tumor is a large cell neuroendocrine carcinoma.

18. The method of claim 15 , wherein the tumor comprises ovarian cancer.

19. The method of claim 15 , wherein the tumor comprises prostate cancer.

20. The method of claim 15 , wherein the tumor comprises medullary thyroid cancer.

21. The method of claim 15 , wherein the tumor comprises renal cancer.

22. The method of claim 11 , wherein the linker comprises a cleavable linker.

23. The method of claim 11 , wherein:
R 2 is R, wherein R is a C 5-20 aryl group;
R 6 and R 9 are H;
R 7 is OR, and wherein R is a C 1 alkyl;
Q is O, and wherein R 11 is H; and/or
X and X″ are O.

24. A method of treating a recurrent tumor in a subject, the method comprising administering to the subject a therapeutically effective amount of an antibody drug conjugate (ADC), or a pharmaceutically acceptable salt thereof, wherein the antibody drug conjugate (ADC) comprises the formula M-[L-D]n, wherein:
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213;
L comprises a linker;
D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring c

Assignees

• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Saunders Laura
• Dylla Scott J
• Foord Orit
• Liu David
• Torgov Michael
• Shao Hui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07D487/16

  Peri-condensed systems · CPC title